There are currently 68 clinical trials in Irving, Texas looking for participants to engage in research studies. Trials are conducted at various facilities, including University Hills Clinical Research, Pfizer Investigational Site, NEXT- Oncology Dallas and US Oncology Investigational Products Center (IPC). Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment
Recruiting
This study is open to adults 18 years and older with advanced or metastatic non-small cell lung cancer. People can join the study if they have tumours with HER2 mutations and have not yet received any systemic therapy including chemotherapy for advanced or metastatic lung cancer. The purpose of this study is to find out whether a medicine called zongertinib (BI 1810631) can slow down the worsening of advanced non-small cell lung cancer better than the standard treatment available. Zongertinib ma... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/22/2025
Locations: Clearview Cancer Institute, Huntsville, Alabama
Conditions: Lung Cancer, Non-squamous, Non-small Cell
Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
Recruiting
The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to standard(s) of care (SOC) treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/17/2025
Locations: Texas Oncology - Central South, Irving, Texas
Conditions: Pancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma
A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)
Recruiting
The main purpose of this study is to assess the effectiveness of adding tirzepatide to ixekizumab therapy in standard clinical practice in participants with moderate-to-severe PsA and obesity or overweight with at least 1 weight-related comorbidity. The study will last up to 12 months.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/17/2025
Locations: AARA Clinical Research - Lone Star Arthritis and Rheumatology Associates - Irving, Irving, Texas
Conditions: Psoriatic Arthritis, Overweight or Obesity
A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)
Recruiting
The main purpose of this study is to evaluate the safety and efficacy of donanemab in participants with preclinical Alzheimer's Disease (AD). Approximately 800 additional participants will be enrolled in a 12-month addendum to assess safety of a different titration regimen.
Gender:
ALL
Ages:
Between 65 years and 80 years
Trial Updated:
04/17/2025
Locations: Optum Infusion - Irving, Irving, Texas
Conditions: Alzheimer Disease
A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130850 in Participants With Advanced Solid and Hematologic Tumors
Recruiting
A FIH study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of VVD-130850, as single agent and in combination with checkpoint inhibition, in participants with advanced solid and hematologic tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/16/2025
Locations: NEXT Dallas, Irving, Texas
Conditions: Advanced Solid Tumors, Advanced Hematologic Tumors
A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors
Recruiting
A FIH dose escalation and dose expansion study to evaluate VVD-130037 in participants with advanced solid tumors as a single agent, in combination with docetaxel, and in combination with paclitaxel.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/16/2025
Locations: NEXT Dallas, Irving, Texas
Conditions: Advanced Solid Tumors
Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab
Recruiting
The primary objective of this study is to compare the efficacy of tarlatamab plus durvalumab with durvalumab alone on prolonging overall survival (OS).
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
04/16/2025
Locations: US Oncology Research Investigational Products Center, Irving, Texas
Conditions: Extensive-Stage Small-Cell Lung Cancer, Small-Cell Lung Cancer
A Phase 2 Study of AMG 193 in Participants With MTAP-deleted Advanced NSCLC
Recruiting
The main objective of the study is to characterize safety and efficacy of 2 dose levels of AMG 193 by investigator, and to evaluate AMG 193 monotherapy efficacy by Blinded Independent Central Review (BICR).
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
04/16/2025
Locations: US Oncology Research Investigational Products Center, Irving, Texas
Conditions: MTAP-deleted NSCLC
A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression
Recruiting
The primary objectives of this study are to observe the safety and tolerability of bemarituzumab and to evaluate preliminary antitumor activity.
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
04/16/2025
Locations: US Oncology Research Investigational Products Center, Irving, Texas
Conditions: Solid Tumors
A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-159642 in Participants With Advanced Solid Tumors
Recruiting
A FIH study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary anti-tumor activity of VVD-159642, a rat sarcoma viral oncogene-phosphatidylinositol 3-kinase alpha (RAS-PI3Kα) inhibitor, as a single agent and in combination with either sotorasib or trametinib in participants with advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/16/2025
Locations: NEXT Dallas, Irving, Texas
Conditions: Advanced Solid Tumors
A Study of SGN-B6A in Advanced Solid Tumors
Recruiting
This trial will look at a drug called sigvotatug vedotin (SGN-B6A) alone and with pembrolizumab, with or without chemotherapy, to find out whether it is safe for people who have solid tumors. It will study sigvotatug vedotin to find out what its side effects are. A side effect is anything the drug does besides treating cancer. It will also study whether sigvotatug vedotin works to treat solid tumors. The study will have four parts. * Part A of the study will find out how much sigvotatug vedoti... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/16/2025
Locations: US Oncology Investigational Product Center (IPC), Irving, Texas
Conditions: Cutaneous Squamous Cell Cancer, Exocrine Pancreatic Adenocarcinoma, Carcinoma, Non-small Cell Lung, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Ovarian Neoplasms, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Stomach Neoplasms, HER2 Negative Breast Neoplasms, Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Efficacy and Safety of Frexalimab (SAR441344) in the Treatment of Systemic Lupus Erythematosus
Recruiting
This is a multinational, randomized, placebo-controlled, parallel treatment, Phase 2, double-blind, 2 arm study evaluating the efficacy and safety of SAR441344 in comparison with placebo in the treatment of participants aged 18 to 70 years with active Systemic Lupus Erythematosus (SLE). Study details include: * Study duration: 36 weeks * Treatment duration: 24 weeks * Visit frequency: every 2 weeks
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
04/15/2025
Locations: AARA Clinical Research - Lone Star Arthritis & Rheumatology Associates - Irving- Site Number : 8400024, Irving, Texas
Conditions: Systemic Lupus Erythematosus